23IKIGAI Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 85

Employees

  • Latest Deal Type
  • Later Stage VC
  • (Cancelled)

  • Latest Deal Amount
  • $200M

  • Investors
  • 16

23IKIGAI General Information

Description

Developer of advanced gene therapeutics intended for the treatment and prevention of medical conditions like cancer and diseases of aging. The company makes molecular medicines and nutrigenomic formulations and has co-developed, along with being the sole licensee of cancer prognostic and diagnostic technology, providing medical professionals with tools to diagnose and treat cancer and diseases related to aging.

Contact Information

Website
tzarlabs.uk
Formerly Known As
Epigeneres
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101, 1st Floor, Todi Building, Mathuradas Mills Compound
  • Senapati Bapat Marg, Lower Parel West
  • Mumbai, Maharashtra 400013
  • India
+91 022
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 101, 1st Floor, Todi Building, Mathuradas Mills Compound
  • Senapati Bapat Marg, Lower Parel West
  • Mumbai, Maharashtra 400013
  • India
+91 022

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

23IKIGAI Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 10-Sep-2024 $200M Cancelled Generating Revenue
3. Later Stage VC (Series B) 03-Oct-2024 Completed Generating Revenue
2. Later Stage VC 04-Jun-2018 $1.77M $2.65M Completed Product In Beta Test
1. Angel (individual) 25-Feb-2016 $881K $881K Completed Product In Beta Test
To view 23IKIGAI’s complete valuation and funding history, request access »

23IKIGAI Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 1,506 $0.119325 $475.39 $475.39 1x $475.39 5.88%
To view 23IKIGAI’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

23IKIGAI Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

23IKIGAI Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Angel (individual) Minority
Dominor Venture Capital Minority
East River Advisors Other Minority
JITO Incubation & Innovation Foundation Accelerator/Incubator Minority
You’re viewing 5 of 16 investors. Get the full list »

23IKIGAI FAQs

  • When was 23IKIGAI founded?

    23IKIGAI was founded in 2012.

  • Where is 23IKIGAI headquartered?

    23IKIGAI is headquartered in Mumbai, India.

  • What is the size of 23IKIGAI?

    23IKIGAI has 85 total employees.

  • What industry is 23IKIGAI in?

    23IKIGAI’s primary industry is Drug Discovery.

  • Is 23IKIGAI a private or public company?

    23IKIGAI is a Private company.

  • What is 23IKIGAI’s current revenue?

    The current revenue for 23IKIGAI is .

  • How much funding has 23IKIGAI raised over time?

    23IKIGAI has raised $10.1M.

  • Who are 23IKIGAI’s investors?

    , , Dominor, East River Advisors, and JITO Incubation & Innovation Foundation are 5 of 16 investors who have invested in 23IKIGAI.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process